Journal of Cancer Research and Immuno-Oncology
Open Access
ISSN: 2684-1266
ISSN: 2684-1266
Yiling Li
Department of Clinical Laboratory, China
Scientific Tracks Abstracts: J Cancer Res Immunooncol
MicroRNA-92a (miR-92a) may serve as a novel promising biomarker in multiple cancers including colorectal cancer (CRC). However, the diagnostic accuracy and the underlying molecular mechanism of miR-92a in CRC is poorly understood. We first carried out meta-analysis and found that serum/plasma miR-92a yield better diagnostic efficacy when compared to stool samples and CRC tissues. And this finding was validated by our independent study through stool sample. Multiple bioinformatics assay indicated that miR-92a expression was positively correlated with heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) expression and closely related with the clinical characteristics of CRC. Experimental evidence shown that knockdown of HNRNPA2B1 could significantly decreased miR-92a expression and secretion in RKO cells. HNRNPA2B1 mediated miR-92a via with m6A RNA modification. These findings indicate that HNRNPA2B1-m6A RNA modification derived MircoRNA-92a upregulation and section from the local CRC acts a candidate non-invasive serum biomarker in colorectal cancer. Our study provides a novel insight into miR-92a mechanisms in relation to both expression and secretion for CRC diagnosis.
Yiling Li, PhD in Clinical Laboratory Diagnostics, State Key Laboratory of Molecular Oncology, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Specialized in the cancer diagnosis of biomarker and epigenetic modification. Currently, five papers of SCI journal have been published, respectively in Cancers, Frontier in Oncology, Frontier in Cell and Developmental biology, Communications Biology and Oncology Reports journals, with the total impact factors reaching 29 points.